Latest news with #Pharmaceuticals
Yahoo
6 hours ago
- Business
- Yahoo
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy's Laboratories, Hetero, Emcure Pharmaceuticals, Eva Pharma, Ferozsons Laboratories, Mylan (Viatris), ViiV Healthcare, Janssen Pharmaceuticals (Johnson & Johnson), Merck & Co. Inc and others. Austin, TX, USA, July 30, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database.'According to the latest research study, the demand of the global Lenacapavir Injection Market size & share was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach a value of around USD 5.68 Billion by 2034, at a compound annual growth rate (CAGR) of about 5.1% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Overview As per the industry experts at CMI, Market participants, such as Gilead Sciences, are concentrating on ultra-long-acting antiretroviral therapies for HIV treatment adherence challenges, with Gilead Sciences focusing on Lenacapavir Injection market. Innovations focus on subcutaneous delivery systems, dosing intervals, and pharmacokinetics. Collaborations with public health and clinical organizations are propelling international approvals and access. There are further combination regimens and formulation innovations targeted at HIV with multidrug resistance. Market expansion occurs in low-income countries with equitable pricing, reinforcing social responsibility and supporting ESG objectives. Responsibly managed corporations fill the gaps for global therapy and preventive health care. Key Trends & Drivers Long-Acting HIV Treatment Demand: The treatment lenacapavir, which is administered biannually, is a game changer for patients who have difficulty adhering to daily oral regimens. Lenacapavir's long acting form decreases adherence-related complications and mitigates pill fatigue while improving overall patient convenience especially in low resource settings. Health systems are adopting long-acting injectables as part of simplified HIV care models. This is most notable in high burden areas where providers seek long-term treatments that preserve viral load suppression during periods of infrequent monitoring. This shifts convenience to the provider, which is currently driving adoption globally. Rising Prevalence of Multidrug-Resistant HIV: The clinical challenge posed by an increasing population of patients suffering from multi-drug resistant HIV infections is effectively met by lenacapavir. Lenacapavir, unlike other traditional antiretroviral therapies, maintains its position as a lifeline for individuals requiring extensive treatment history due to its activity against a wide range of HIV strains. Such resilience increases its applicability for salvage therapy regimens. Its novel action as a capsid inhibitor enables it to plug therapeutic holes left by other drugs. Hence, cases of MDR HIV, particularly in Sub-Saharan Africa and Eastern Europe, are increasing and lenacapavir is demanded as a critical component of resistance management. Request a Customized Copy of the Lenacapavir Injection Market Report @ Regulatory Support and Global Access Programs: Lenacapavir is approved and awarded incentives by the FDA, EMA, and Health Canada as a treatment for HIV due to its unique features and promise. These approvals have expedited regional access. At the same time, Gilead collaborates with PEPFAR, WHO, and the Global Fund to incorporate Lenacapavir into their treatment programs for middle and lower-income countries. Such collaborations enhance access and coverage especially in regions highly affected by HIV. The combination of these actions—regulatory, humanitarian, and commerce—strengthens the global supply strategy for lenacapavir while keeping the commercial strategy seamless. Technological Advancements in Injectable Formulations: New technologies that enable extended release of therapeutics through injections have made it possible for Lenacapavir to maintain therapeutic levels for longer periods. Advances in administering injectable therapeutics have made them easier to submit to put to use in almost all healthcare settings, such as initiated bioavailable, lower Mentors devices, and even autoprinters. These improvements also lessen the workload placed on health facilities. They offer discreet and effective treatment to patients. Reduced clinic appointment attendance caters to both rural and urban areas, improving the healthcare system as a whole. The evolution of injectable technologies strengthens Lenacapavir's formulation strategy, resulting in its dominant position as a next-generation platform. Report Scope Feature of the Report Details Market Size in 2025 USD 3.66 Billion Projected Market Size in 2034 USD 5.68 Billion Market Size in 2024 USD 3.5 Billion CAGR Growth Rate 5.1% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Indication, Formulation, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Lenacapavir Injection report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Lenacapavir Injection report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Lenacapavir Injection Market Report @ SWOT Analysis Strengths: Lenacapavir offers a groundbreaking, long-acting antiretroviral solution, allowing biannual dosing which significantly improves patient compliance compared to daily oral therapies. Its novel capsid inhibitor mechanism targets both treatment-naïve and drug-resistant HIV strains. Backed by strong clinical trial results and regulatory approvals like the FDA and EMA, it provides pharmaceutical firms with first-mover advantages and intellectual property exclusivity that strengthens market leadership in HIV care. Weaknesses: Increased cold-chain logistics of the injectable form in low resource areas add to already heightened innovative manufacturing costs. Further, the need for provider administration may turn away needle averse patients which adds to an already strained healthcare infrastructure. Adoption by clinicians, particularly in conservative markets, is stifled by the conservative reimbursement policies from insurers, mainly due to the lack of long-term safety data of this new class of therapeutics. Opportunities: As the global prevalence of HIV increases, lenacapavir takes the role of addressing the enduring adherence challenges. Further, expansion through co-formulation opens up the potential for additional wide-ranging clinical studies for preventive (PrEP) therapies. Working with global health organizations, strategic relationships with low income countries can help penetrate poorly served markets. Inclusion into national HIV programs increases public sector uptake while amplifying global impact. Threats: Lenacapavir is facing competing long-acting antiretroviral agents such as cabotegravir and rilpivirine-based therapies. The erosion of profit margins due to expiring patents, the development of biosimilars and competition from global procurement agencies may increase costs. Emerging issues related to safety or viral resistance can impact clinical confidence significantly. Revenue growth potential from key emerging markets may be restricted by regulatory delays, which in turn slows down market entry. Request a Customized Copy of the Lenacapavir Injection Market Report @ Key questions answered in this report: What is the size of the Lenacapavir Injection market and what is its expected growth rate? What are the primary driving factors that push the Lenacapavir Injection market forward? What are the Lenacapavir Injection Industry's top companies? What are the different categories that the Lenacapavir Injection Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Lenacapavir Injection market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The Lenacapavir Injection Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: The Region's market for lenacapavir is led by the U.S. due to early regulatory approvals, infrastructure, and a high rate of HIV prevalence. in addition to reimbursement and innovative clinical programs, there are also major research institutions in the region. uptake is higher than average among hard-to-treat patient groups and during public health programs. there still remains a significant opportunity for PRP and other injectable treatment options. therefore, prep commercialization continues to be innovative in North America. Europe: Europe also represents a large market opportunity for lenacapavir due to its ema approval and geographical access programs. other health systems have started integrating the drug into their HIV treatment framework. countries such as Germany, France, and the UK are early adopters along with support for injectable based regimens. the European region also provides a shift towards sustainable healthcare delivery in the management of infectious diseases. Asia-Pacific: The region comprises countries with a high HIV burden, such as Thailand, India, and China. It is an emerging growth area. Some markets are still awaiting regulatory approval, but aid-funded rollouts and international subsidy programs are facilitating access. The region's population size, coupled with rising healthcare spending, makes it ready for long-acting antiretroviral therapies. The region also poses challenges of affordability and cold-chain maintenance. If these are solved, particularly through local licensing and manufacturing, the next five years could witness exponential growth of the region. LAMEA: The LAMEA Lenacapavir market is marked by the expanding need for long-acting treatments in healthcare access-challenged regions. Brazil, Argentina, and Chile are leading as they have more advanced public health systems. While regulations are still being updated, NGOs and global donors are providing critical early access distribution. Access is especially acute for underresourced groups, and the region is seen as a prime candidate for future generic penetration. These will also help generate broader market acceptance through strategic partnerships and government tenders. Request a Customized Copy of the Lenacapavir Injection Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at of the prominent players in the Lenacapavir Injection Market: Gilead Sciences Reddy's Laboratories Hetero Emcure Pharmaceuticals Eva Pharma Ferozsons Laboratories Mylan (Viatris) ViiV Healthcare Janssen Pharmaceuticals (Johnson & Johnson) Merck & Co. Inc Others Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Pharmaceutical Metal Detector Market: Pharmaceutical Metal Detector Market Size, Trends and Insights By Technology (Magnetic Field Detectors, Multi-frequency Detectors, X-Ray Inspection with Metal Detectors), By Application (Quality Control, Contaminant Detection, Packaging, Compliance), By End-user (Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Biopharmaceutical Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Deep Eutectic Solvents Market: Deep Eutectic Solvents Market Size, Trends and Insights By Product (Organic Salts + Metal Salts, Organic Salts + Metal Hydrates, Organic Salts + Hydrogen Bond Donor, Metal Chlorides + Hydrogen Bond Donor), By End-use (Pharmaceuticals & Healthcare, Food & Beverages Processing, Cosmetics & Personal Care, Chemical & Materials Industry), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Medical Equipment Calibration Services Market: Medical Equipment Calibration Services Market Size, Trends and Insights By Service (In-house, Third-party Services, Original Equipment Manufacturers (OEMs)), By End-use (Hospitals, Clinical Laboratories), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 North America Oral Care Market: North America Oral Care Market Size, Trends and Insights By Product Type (Toothbrush, Manual, Electric (Rechargeable), Battery-powered (Non-rechargeable), Others, Toothpaste, Gel, Polish, Paste, Powder, Mouthwash/Rinse, Medicated, Non-medicated, Denture Products, Cleaners, Fixatives, Floss, Others, Dental Accessories, Cosmetic Whitening Products, Fresh Breath Dental Chewing Gum, Tongue Scrapers, Fresh Breath Strips, Others, Oral Irrigators, Mouth Freshener Sprays), By Age Group (Kids, Adults, Geriatric), By Type (Countertop, Cordless), By Application (Home, Dentistry), By Sales Channel (Hypermarkets/Supermarkets, Specialty Stores, Drug Stores &Pharmacies, Convenience Stores, Online Sales Channel), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 AI in Synthetic Biology Market: AI in Synthetic Biology Market Size, Trends and Insights By Technology (Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics), By Application (Healthcare & Medicine, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Alzheimer's Drug Market: Alzheimer's Drug Market Size, Trends and Insights By Type of Drug (Disease-Modifying Therapies (DMTs), Symptomatic Therapies), By Application (Amyloid-Targeting Agents, Tau-Targeting Agents, Cholinesterase Inhibitors, NMDA Antagonists, Other Agents), By End User (Hospitals, Clinics, Home Care Settings), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Cell Cancer Vaccine Market: Japan Cell Cancer Vaccine Market Size, Trends and Insights By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Oncolytic Viruses), By Indication (Prostate Cancer, Cervical Cancer), By Technology (Peptide-based Vaccines, Vector-based Vaccines, DNA/RNA-based Vaccines), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 mRNA Cancer Vaccine Market: mRNA Cancer Vaccine Market Size, Trends and Insights By Cancer Type (Melanoma, Lung Cancer (NSCLC), Prostate Cancer, Pancreatic Cancer, Colorectal Cancer), By Application/Use Case (Therapeutic Cancer Vaccines, Preventive/Prophylactic Cancer Vaccines), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Carriers, Electroporation), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Lenacapavir Injection Market is segmented as follows: By Indication HIV Treatment Pre-Exposure Prophylaxis (PrEP) By Formulation Injectable Oral Tablets By Distribution Channel Branded Medicine Generic Medicine Click Here to Get a Free Sample Report of the Global Lenacapavir Injection Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Lenacapavir Injection Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Lenacapavir Injection Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Lenacapavir Injection Market? What Was the Capacity, Production Value, Cost and PROFIT of the Lenacapavir Injection Market? What Is the Current Market Status of the Lenacapavir Injection Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Lenacapavir Injection Market by Considering Applications and Types? What Are Projections of the Global Lenacapavir Injection Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Lenacapavir Injection Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Lenacapavir Injection Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Lenacapavir Injection Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Lenacapavir Injection Industry? Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Reasons to Purchase Lenacapavir Injection Market Report Lenacapavir Injection Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Lenacapavir Injection Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Lenacapavir Injection Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Lenacapavir Injection Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Lenacapavir Injection market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Lenacapavir Injection market analysis. The competitive environment of current and potential participants in the Lenacapavir Injection market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Lenacapavir Injection market should find this report useful. The research will be useful to all market participants in the Lenacapavir Injection industry. Managers in the Lenacapavir Injection sector are interested in publishing up-to-date and projected data about the worldwide Lenacapavir Injection market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Lenacapavir Injection products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Lenacapavir Injection Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @
Bloomberg
a day ago
- Business
- Bloomberg
Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. It will cut administrative, sales and research jobs, as well as reduce its global real estate holdings, the Rahway, New Jersey-based company said in a statement Tuesday. Merck expects the restructuring to be completed by the end of 2027, the year before Keytruda's key patents expire and the drug faces US government price cuts.
Associated Press
a day ago
- Business
- Associated Press
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £250,000 and Director's Dealing
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Secures £250,000 to continue its Phase 1 Clinical Trials And Director's Dealing LONDON, UK / ACCESS Newswire / July 29, 2025 / Introduction Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of £250,000 via an allotment to Vladislav Sandler of 133,690 new ordinary shares of £0.01 each ('New Ordinary Shares') at an issue price of 187p, representing a premium to the present market price (the 'Issue Price'). The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ('R/R AML'). As shareholders will be aware, the first two patients have now been treated with HG-CT-1 with the four-week safety trials successfully completed and with encouraging early signs of efficacity. Issuance of the New Ordinary Shares The Company is currently unable to issue and admit New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus. Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO and director of the Company, to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation. Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to a small group of individual investors who made an approach wishing to make a new investment in the Company; they will acquire the Subscription Shares from Mr Sandler at the price of 187p per share. Warrants Concurrent with the purchase of the New Ordinary Shares, the new investor group will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 187p ('Exercise Price'), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price. Total Voting Rights Application will be made for the 133,690 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to theFCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 7 August 2025 ('Admission'). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,727,229. The above figure of 4,727,229 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company will keep the market informed of future developments as trials proceed. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 'We are pleased to have attracted funding from this group of investors at a premium to the current price - this reflects their confidence in the progress made by the Company to date and in the long-term prospects of Hemogenyx. The fact that the raise was completed at a premium to the market price demonstrates this confidence and shows that they see considerable upside potential in our share price as we advance HG-CT-1 through clinical development. .' UK Market Abuse Regulation (UK MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Director's Dealing Notification Enquiries: About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City . The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Hemogenyx Pharmaceuticals PLC press release
Bloomberg
a day ago
- Business
- Bloomberg
AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines. Revenue climbed 12% to $14.5 billion, beating estimates. Earnings per share excluding some items rose 10% to $2.17, as expected.
Yahoo
3 days ago
- Business
- Yahoo
Cosmo Pharmaceuticals First Half 2025 Earnings: €0.13 loss per share (vs €4.42 profit in 1H 2024)
Cosmo Pharmaceuticals (VTX:COPN) First Half 2025 Results Key Financial Results Revenue: €51.7m (down 62% from 1H 2024). Net loss: €2.01m (down by 103% from €71.2m profit in 1H 2024). €0.13 loss per share (down from €4.42 profit in 1H 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Cosmo Pharmaceuticals Earnings Insights Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Switzerland. Performance of the Swiss Pharmaceuticals industry. The company's shares are up 2.6% from a week ago. Risk Analysis It is worth noting though that we have found 2 warning signs for Cosmo Pharmaceuticals that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
